An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Key Takeaways An experimental drug can delay disability progression in advanced multiple sclerosis patientsTolebrutinib ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.